cyltezo

November 16, 2017November 16, 2017

EU Approves Humira Biosimilar Cyltezo for Treatment of Chronic Inflammatory Diseases

News

The European Commission recently approved Cyltezo, a biosimilar to Humira (adalimumab), for the treatment of chronic inflammatory diseases in adults and children including inflammatory bowel diseases (IBDs) such as Crohn’s disease ... Read more

August 30, 2017August 30, 2017

FDA Approves Humira Biosimilar Cyltezo for Ulcerative Colitis, Crohn’s Disease, Other Illnesses

News

The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim‘s Cyltezo— a biosimilar of Abbvie’s Humira (adalimumab) — to treat Crohn’s disease, ulcerative colitis and a host of other diseases ranging from ... Read more